| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 331.2 | 287.4 | 296.4 |
| Other income | 7.4 | 8.1 | 7.0 |
| Total income | 338.6 | 295.5 | 303.4 |
| Profit before exceptional items & tax | 19.7 | 9.6 | 22.7 |
| Profit before tax | 19.7 | 9.6 | 22.7 |
| Net profit | 10.5 | 18.5 | 7.7 |
| Operating margin | 5.8% | 3.2% | 7.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +36.40% |
|---|---|
| Net profit, quarter on quarter | -43.20% |
| Revenue, year on year | +11.70% |
| Operating profit, year on year | -21.70% |
| Operating profit, quarter on quarter | +720.00% |
BSE results filing, NSE: SHALBY. Figures extracted from the filing.
Shalby Ltd: key numbers
- Share price
- ₹147.12
- Market cap
- ₹1,589 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 40.4×Sector 57.8×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Management Change
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Annual General Meeting
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby Earnings Call Transcript: Key Takeaways
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
- Call
- Guides 20% growth
Shalby Investor Presentation: Key Takeaways
Shalby Limited reported Q1 FY27 consolidated revenue of ₹3,386 mn, up 11.6% YoY, and PAT of ₹105 mn, up 36.7% YoY. Focus remains on orthopedic leadership and expanding implant business.
Shalby Earnings Call: Key Takeaways
Shalby Limited reported Q4 FY26 consolidated revenue growth of 9.4% YoY. Key focus on MedTech turnaround with positive EBITDA and expansion in oncology services.
Shalby Earnings Call: Key Takeaways
Shalby delivered strong Q4 growth with EBITDA up 43.1% YoY, driven by operational efficiency and recovery in the implant business despite geopolitical headwinds in international segments.